Copy to clipboard 
RoosterBio raised over US $15MM in an initial Series B financing round led by Dynamk Capital. Existing and new investor interest led to an oversubscribed round; the final round is expected to close with additional investors by the end of August, totaling ~$22MM raised.
The company seeks to simplify human mesenchymal stem/stromal cell (hMSC) biomanufacturing.
The infusion will expand and scale the RoosterBio team as its customer base grows internationally, and will bolster R&D for their next-generation cell and gene therapy solutions.
“It is critical that we empower scientists to get innovative products to the market more efficiently in order to develop life-saving cures,” said Daniella Kranjac, Founding Partner of Dynamk Capital. “RoosterBio’s pioneering biotechnology platform is driving the revolutionary field of regenerative medicine which has the potential to develop therapies for previously untreatable diseases and conditions. We look forward to helping RoosterBio scale their business and make their technology more broadly available.”
hMSCs are a necessary raw material for many regenerative medicine products such as cell-based therapies, engineered tissues or combination products. RoosterBio has transitioned hMSCs from a scarce to an abundant resource by increasing their availability and manufacturability, subsequently decreasing the cost and the complexity required to incorporate these active living cells into regenerative medicine products.
Source: RoosterBio, Inc.
